Sorafenib, a systemic therapy for hepatocellular carcinoma

Sorafenib, a systemic therapy for hepatocellular carcinoma

Hepatocellular carcinoma is a lethal disease that requires a multidisciplinary approach and management. Surgical therapy offers long-term survival; however, few patients are candidates. There has been no accepted systemic therapy for this disease until recently. This article briefly discusses the ro...

Full description

Bibliographic Details
Main Authors: Nahum Méndez-Sánchez;, Francisco Vásquez-Fernández;, Daniel Zamora-Valdés;, Misael Uribe
Format: Article
Language:English
Published: Elsevier 2008-01-01
Series:Annals of Hepatology
Subjects:
Liver cancer
hepatocellular carcinoma
HCV
HBV
sorafenib
Online Access:http://www.sciencedirect.com/science/article/pii/S1665268119318861
id doaj-b9cb744433604f4d8549fedf93f27890
record_format Article
spelling doaj-b9cb744433604f4d8549fedf93f278902021-06-09T05:56:14ZengElsevierAnnals of Hepatology1665-26812008-01-01714651Sorafenib, a systemic therapy for hepatocellular carcinomaNahum Méndez-Sánchez;0Francisco Vásquez-Fernández;1Daniel Zamora-Valdés;2Misael Uribe3Liver Unit, Medica Sur Clinic & Foundation, Mexico City, Mexico; Address for correspondence:Liver Unit, Medica Sur Clinic & Foundation, Mexico City, MexicoLiver Unit, Medica Sur Clinic & Foundation, Mexico City, MexicoLiver Unit, Medica Sur Clinic & Foundation, Mexico City, MexicoHepatocellular carcinoma is a lethal disease that requires a multidisciplinary approach and management. Surgical therapy offers long-term survival; however, few patients are candidates. There has been no accepted systemic therapy for this disease until recently. This article briefly discusses the role of RAS/RAF/MEK/ ERK signaling pathway in the pathogenesis of the disease and the promising role of sorafenib for advanced disease.http://www.sciencedirect.com/science/article/pii/S1665268119318861Liver cancerhepatocellular carcinomaHCVHBVsorafenib
collection DOAJ
language English
format Article
sources DOAJ
author Nahum Méndez-Sánchez;
Francisco Vásquez-Fernández;
Daniel Zamora-Valdés;
Misael Uribe
spellingShingle Nahum Méndez-Sánchez;
Francisco Vásquez-Fernández;
Daniel Zamora-Valdés;
Misael Uribe
Sorafenib, a systemic therapy for hepatocellular carcinoma
Annals of Hepatology
Liver cancer
hepatocellular carcinoma
HCV
HBV
sorafenib
author_facet Nahum Méndez-Sánchez;
Francisco Vásquez-Fernández;
Daniel Zamora-Valdés;
Misael Uribe
author_sort Nahum Méndez-Sánchez;
title Sorafenib, a systemic therapy for hepatocellular carcinoma
title_short Sorafenib, a systemic therapy for hepatocellular carcinoma
title_full Sorafenib, a systemic therapy for hepatocellular carcinoma
title_fullStr Sorafenib, a systemic therapy for hepatocellular carcinoma
title_full_unstemmed Sorafenib, a systemic therapy for hepatocellular carcinoma
title_sort sorafenib, a systemic therapy for hepatocellular carcinoma
publisher Elsevier
series Annals of Hepatology
issn 1665-2681
publishDate 2008-01-01
description Hepatocellular carcinoma is a lethal disease that requires a multidisciplinary approach and management. Surgical therapy offers long-term survival; however, few patients are candidates. There has been no accepted systemic therapy for this disease until recently. This article briefly discusses the role of RAS/RAF/MEK/ ERK signaling pathway in the pathogenesis of the disease and the promising role of sorafenib for advanced disease.
topic Liver cancer
hepatocellular carcinoma
HCV
HBV
sorafenib
url http://www.sciencedirect.com/science/article/pii/S1665268119318861
work_keys_str_mv AT nahummendezsanchez sorafenibasystemictherapyforhepatocellularcarcinoma
AT franciscovasquezfernandez sorafenibasystemictherapyforhepatocellularcarcinoma
AT danielzamoravaldes sorafenibasystemictherapyforhepatocellularcarcinoma
AT misaeluribe sorafenibasystemictherapyforhepatocellularcarcinoma
_version_ 1721388615239467008

Similar Items